Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 659-659
Open Access | Times Cited: 301

Showing 1-25 of 301 citing articles:

Carbon Dot Based Carbon Nanoparticles as Potent Antimicrobial, Antiviral, and Anticancer Agents
Narmin Hamaamin Hussen, Aso Hameed Hasan, Yar Muhammed FaqiKhedr, et al.
ACS Omega (2024) Vol. 9, Iss. 9, pp. 9849-9864
Open Access | Times Cited: 25
Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials
Jinjiang Wang, Jiaxi Li, Jiao Liu, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 512-512
Open Access | Times Cited: 22
Research progress of organic photothermal agents delivery and synergistic therapy systems
Yuan Li, Haolong Qi, Yingjie Geng, et al.
Colloids and Surfaces B Biointerfaces (2024) Vol. 234, pp. 113743-113743
Closed Access | Times Cited: 21
Oxidative Stress and Age-Related Tumors
Emma Di Carlo, Carlo Sorrentino
Antioxidants (2024) Vol. 13, Iss. 9, pp. 1109-1109
Open Access | Times Cited: 16
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
Alberto Gabizón, Shira Gabizon–Peretz, Shadan Modaresahmadi, et al.
BMJ Oncology (2025) Vol. 4, Iss. 1, pp. e000573-e000573
Open Access | Times Cited: 7
Cyclodextrin-based nanocarriers as promising scaffolds for overcoming challenges of doxorubicin delivery in cancer chemotherapy
Sara Payamifar, Amin Foroozandeh, Mehrab Pourmadadi, et al.
Carbohydrate Polymer Technologies and Applications (2025), pp. 100677-100677
Open Access | Times Cited: 6
In Vitro Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes
Islam Alfreahat, Hamdi Nsairat, Ibrahim Al‐Deeb, et al.
Technology in Cancer Research & Treatment (2025) Vol. 24
Open Access | Times Cited: 2
Applications and Enhancement Strategies of ROS-based Non-invasive Therapies in Cancer Treatment
Qiuyan Guo, Yingnan Tang, Shengmei Wang, et al.
Redox Biology (2025), pp. 103515-103515
Open Access | Times Cited: 2
Current Advances in the Therapeutic Potential of Scutellarin: Novel Applications, Mechanisms, and Future Challenges.
Great Iruoghene Edo, Alice Njolke Mafe, Patrick Othuke Akpoghelie, et al.
Phytomedicine Plus (2025), pp. 100754-100754
Open Access | Times Cited: 2
DNA dendrimer-based nanocarriers for targeted Co-delivery and controlled release of multiple chemotherapeutic drugs
Yao Tian, Mengqiu Sun, Rui Song, et al.
RSC Advances (2025) Vol. 15, Iss. 4, pp. 2981-2987
Open Access | Times Cited: 2
Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?
Adrianna Gielecińska, Mateusz Kciuk, Esam Bashir Yahya, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189024-189024
Open Access | Times Cited: 35
Neutrophil extracellular traps mediate cardiomyocyte ferroptosis via the Hippo–Yap pathway to exacerbate doxorubicin-induced cardiotoxicity
Peng Zhao, You Li, Xiangli Xu, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 15
Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment
Natalia I. Agalakova
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 945-945
Open Access | Times Cited: 13
Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account
Roberta Vitale, Stefania Marzocco, Ada Popolo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7477-7477
Open Access | Times Cited: 12
A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer
Anjali Bisht, Dubey Avinash, Kantrol Kumar Sahu, et al.
Drug Delivery and Translational Research (2024)
Closed Access | Times Cited: 11
Uncovering the Cardioprotective Potential of Diacerein in Doxorubicin Cardiotoxicity: Mitigating Ferritinophagy-Mediated Ferroptosis via Upregulating NRF2/SLC7A11/GPX4 Axis
Rehab M. El‐Gohary, Asmaa H. Okasha, Alaa H. Abd El-Azeem, et al.
Antioxidants (2024) Vol. 13, Iss. 4, pp. 493-493
Open Access | Times Cited: 8
The protective effects of esculetin against Doxorubicin‐Induced hepatotoxicity in rats: Insights into the modulation of Caspase, FOXOs, and heat shock protein pathways
Duygu Kizir, Esra Nur Yeşilkent, Neslihan Öztürk, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 8
GV1001, hTERT Peptide Fragment, Prevents Doxorubicin-Induced Endothelial-to-Mesenchymal Transition in Human Endothelial Cells and Atherosclerosis in Mice
Wei Chen, Seo‐Jin Kim, Sharon Kim, et al.
Cells (2025) Vol. 14, Iss. 2, pp. 98-98
Open Access | Times Cited: 1
Inhibition of NETs prevents doxorubicin-induced cardiotoxicity by attenuating IL-18-IFN-γ-Cx43 axis induced cardiac conduction abnormalities
Kun Li, Kunmao Jiang, Yu Wang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 114016-114016
Closed Access | Times Cited: 1
Mitochondrial segmentation and function prediction in live-cell images with deep learning
Yang Ding, Jintao Li, Jiaxin Zhang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance
Hanan Elimam, Mohamed Bakr Zaki, Mai A. Abd‐Elmawla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access | Times Cited: 1
Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
Jarosz-Biej Magdalena, Czapla Justyna, C Renshaw Joanna, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access | Times Cited: 1
Hollow mesoporous prussian blue nanozymes alleviate doxorubicin-induced cardiotoxicity by restraining oxidative stress associated with Nrf2 signaling
Fang Wang, Ke Wang, Baoru Fang, et al.
Journal of Colloid and Interface Science (2025) Vol. 686, pp. 1074-1088
Closed Access | Times Cited: 1
Folic Acid-Conjugated Magnetic Oleoyl-Chitosan Nanoparticles for Controlled Release of Doxorubicin in Cancer Therapy
Banendu Sunder Dash, Yuan T. Lai, Jyh‐Ping Chen
Nanomaterials (2025) Vol. 15, Iss. 6, pp. 415-415
Open Access | Times Cited: 1
Irisin protects against doxorubicin-induced cardiotoxicity by improving AMPK-Nrf2 dependent mitochondrial fusion and strengthening endogenous anti-oxidant defense mechanisms
Caili Zhuo, Juan-Juan Xin, Wenjing Huang, et al.
Toxicology (2023) Vol. 494, pp. 153597-153597
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top